epatitis C virus (HCV) is a major public health problem and a leading cause of chronic liver disease. An estimated 170 million individuals are infected worldwide. Diagnostic assays for HCV include serological assays for the detection of HCV-specific antibodies and molecular assays aiming at sensitive detection of HCV RNA in plasma or serum. The detection of HCV RNA is important for distinguishing between acute, chronic, and resolved infections. Quantitative and qualitative detection of HCV RNA is furthermore used to determine treatment response.
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Decision points in the treatment of HCV require both qualitative results generated with an assay with a lower limit of detection (LLOD) of at least 15 IU/ml and quantitative results. Due to the increase of global availability of medication and changes of the epidemiology of HCV genotypes in the Western world, these assays would preferably be equally sensitive for all HCV genotypes (1, 2) . Current methods for the quantitative detection of HCV RNA include endpoint reverse transcription-PCR (RT-PCR), real-time RT-PCR, the branched DNA (bDNA) method, and, for qualitative results, the transcription-mediated amplification (TMA) method (3) (4) (5) (6) . Quantitative endpoint RT-PCRs are increasingly displaced by real-time RT-PCRs because the latter in general have an increased dynamic range, are less prone to contamination, and are easier to automate (7) . An alternative to realtime RT-PCR is a combination of testing with bDNA and TMA where the bDNA test is used for quantification before the start of treatment and at weeks 4 and 12 and TMA is used for sensitive qualitative detection at weeks 12 and beyond, although the testing algorithms are more complex than those used for testing with sensitive real-time RT-PCR.
After the introduction of the cobas AmpliPrep/cobas TaqMan HCV test v1.0 (CAP/CTM v1.0), it became apparent that this test, despite its good performance characteristics with most genotype 1 to 3 strains, underquantifies certain genotype 4 strains and a small percentage of patients infected with genotype 1 (5, 6, (8) (9) (10) . Recently, results obtained with a prototype of a second version of the CAP/CTM HCV test have been described (11) , demonstrating that, after the redesign of primers and addition of a second probe, the problem of underquantification of certain genotype 4 HCV strains was solved. This redesign was used for the development of the Roche cobas AmpliPrep/cobas TaqMan HCV test, v2.0 (CAP/ CTM v2.0). We set out to determine the quantitative and qualitative detection of HCV by the CAP/CTM HCV v2.0 test relative to its major commercially available competitors.
MATERIALS AND METHODS
Patient samples and test materials. Leftover EDTA plasma samples sent to the diagnostic units of the Department of Virology of the Erasmus MC and the Department of Clinical Microbiology of the Amsterdam Medical Center for HCV diagnostics were used in this study. Written informed consent was obtained from each patient, and the study was approved by the Medical Ethical Committee. In addition, plasma samples previously used in a study to validate the performance of the Siemens Versant HCV Genotype 2.0 Products (LiPA; Siemens Healthcare Diagnostics, Den Haag, the Netherlands) test on HCV genotypes 5 and 6 were included (12) . Plasma samples were stored at Ϫ80°C until use. For platform com-parisons, plasma samples were diluted 10 to 200 times with a pool of HCV RNA-negative, RNase-free plasma using a CAS4200 system (Qiagen, Hilden, Germany). Diluted samples were aliquoted into sufficient aliquots to allow testing on all platforms and stored at Ϫ80°C until use. Aliquots tested at the Academic Medical Center Amsterdam were sent on dry ice to prevent multiple freeze-thaw cycles. A separate aliquot was used for each test to prevent multiple freeze-thaw cycles. Plasma samples were selected to have an HCV RNA load of between 115 IU/ml and 100,000 IU/ml after dilution. Genotyping was performed with the Siemens Versant HCV Genotype 2.0 Products (LiPA) (Siemens Healthcare Diagnostics, the Hague, the Netherlands) test on an Auto-LiPA 48 system (Innogenetics, Ghent, Belgium) at the Erasmus MC and by sequencing part of NS5B at the Amsterdam Medical Center (13) . In order to compare HCV RNA quantifications of the different platforms, internationally recognized standards were used: the 2nd WHO international standard (06-100; National Institute for Biological Standards and Control [NIBSC], Potters Bar, United Kingdom) and the Acrometrix HCV genotyping panel (Optiqual 1 to 4; Acrometrix, Benicia, CA). After primary analysis of the data, an outlier analysis was performed. Samples that, after retesting or dilution, were below the lower limit of quantification (LLOQ) in all platforms tested were excluded from the analyses. Samples that differed by more than 0.5 log in one platform compared to the other two platforms tested were retested in the platform that differed from the other two. The result of the retest procedure was used in the study.
Quantitative and qualitative HCV RNA assays. In the present study, all testing procedures for the CAP/CTM HCV v1.0 and v2.0 tests (Roche Molecular Diagnostics, Almere, the Netherlands) were performed at the Erasmus MC. The Siemens Versant HCV RNA 3.0 assay (bDNA) (Siemens Healthcare Diagnostics, the Hague, the Netherlands), Abbott m2000 RealTime HCV assay (Realtime assay) (Abbott Diagnostics, Hoofddorp, the Netherlands), and Siemens Versant HCV qualitative assay were performed at the Amsterdam Medical Center. During routine diagnostics, quantitative detection of HCV was performed with the cobas Amplicor HCV Monitor test using the manual High Pure system (HPS/ CA) and qualitative detection was performed with the cobas AmpliPrep/ cobas Amplicor HCV test, version 2.0 (CAP/CA) (Roche Molecular Diagnostics, Almere, the Netherlands). All assays were performed according to the manufacturer's instructions as described in the respective package inserts.
Data analysis. Data were analyzed using Microsoft Office Excel 2003 and SigmaPlot for Windows, version 10.0.
RESULTS

Validity of testing procedure.
To study whether the dilution procedure and the matrix used to dilute the plasma samples might influence the results of the study, a selection of genotype 1 to 4 samples (10 samples for each genotype) was tested in the CAP/ CTM v2.0 neat and diluted and results were compared. None of the tested samples differed by more than 0.5 log, and the regression coefficient was close to 1 (R 2 ϭ 0.9925), validating the dilution procedure used in this study (data not shown). Platform comparison. To test the standardization of the different platforms with international standards, the Acrometrix genotype panel and a dilution series of the 2nd WHO international standard were tested once with the CAP/CTM v2.0, Realtime, and bDNA assays (Table 1) . No major differences of more than 0.7 log 10 (14) from the expected value were observed between the test platforms except for lower values of the Realtime test on the WHO international standard and the Acrometrix Optiqual genotype 2 sample. The performance of the CAP/CTM v1.0, CAP/CTM v2.0, Realtime assay, and bDNA assay on a panel of HCV RNA-positive samples of diverse genotypes was tested. Due to limited availability of samples, not all samples were tested in all platforms. As a result, 151, 190, 189, and 190 samples were tested in the CAP/CTM v1.0, CAP/CTM v2.0, Realtime assay, and bDNA assay, respectively. For platform comparison, a regression analysis was performed on data plots generated similarly to Bland-Altman plots (plotting the mean of results from the two assays against the difference between results from the two assays) (Fig. 1) . For the calculation of the average viral load per test and regression analysis, only samples tested on all platforms were used and samples recorded below the LLOQ of the CAP/CTM v1.0 (15 IU/ml), the CAP/CTM v2.0 (15 IU/ml), and the Realtime test (12 IU/ml) or below the LLOD of the bDNA (615 IU/ml) were assigned the LLOQ and LLOD values, respectively ( Table 2 ). The average viral loads for the CAP/CTM v1.0, CAP/CTM v2.0, Realtime test, and bDNA assay were 5.25 log, 4.91 log, 4.90 log, and 4.74 log, respectively. The slopes of the regression curves in the Bland-Altman plots were close to zero (Ϫ0.07, Ϫ0.07, and Ϫ0.06) for comparisons of the CAP/CTM v2.0 with the CAP/CTM 1.0, Realtime, and bDNA tests, respectively. The y intercepts were slightly higher than 0 for all three comparisons (0.12, 0.40, and 0.46 for the CAP/ CTM 1.0, Realtime, and bDNA tests, respectively). The regression coefficients of the linear regression analysis were 0.8957, 0.9648, and 0.9372 for the CAP/CTM 1.0, Realtime, and bDNA tests, respectively. Samples recorded below the LLOQ by the Realtime test (1 sample) and the LLOD of the bDNA assay (18 samples) had a viral load around the LLOQ of the corresponding test, while samples recorded below the LLOQ by the CAP/CTM v1.0 (4 samples) had a significantly higher viral load (mean, 3.10E4 IU/ml). The 5= untranslated regions (5=UTR) of the latter 4 samples were sequenced, and all four sequences obtained proved to have the previously reported G145A in combination with A165T mutation in the probe region (data not shown) (11) . None of these four samples were recorded below the LLOQ by the CAP/CTM v2.0 or in any of the other test platforms. The Realtime assay and the CAP/ CTM v2.0 proved to have similar averages for different genotypes ( Table 2 ). The CAP/CTM v1.0 proved to have higher averages for genotypes 1, 3, 5, and 6, while lower average viral loads were recorded for genotypes 2 and 4. The bDNA test recorded on average similar viral loads for genotypes 1 and 5, while lower averages were observed for genotypes 2, 3, 4, and 6.
Qualitative analysis and genotype 4 response-guided therapy. To determine the sensitivity of the CAP/CTM v2.0 test for the qualitative detection of HCV RNA, samples from patients infected with genotype 1, 2, 3, or 4 who were receiving therapy were processed with the TMA assay and the CAP/CTM v2.0 (Table 3) . Samples were selected that were below the LLOD of the bDNA and either TMA negative or TMA positive in our routine diagnostic procedure and subsequently retested with the CAP/CTM v2.0. Equal distributions of patients infected with genotype 1, 2, 3, or 4 were selected in both groups, although, due to limited availability of samples, only a few TMA-positive samples from genotype 2-infected patients could be tested. Samples may be positive or negative for HCV RNA but below the LLOQ and thus unquantified by the CAP/CTM v2.0. Those results are reported as Ͻ15 IU/ml. Qualitative results are reported as "target detected" or "target not detected" by the CAP/CTM v2.0 for samples below the LLOQ. The TMA result was compared with the CAP/CTM v2.0 qualitative result (target detected or target not detected) and the quantitative result (Ͻ15 IU/ml or Ͼ15 IU/ml). The negative predictive value of Longitudinal samples from 21 HCV genotype 4-infected patients who were started on treatment with polyethylene glycolinterferon (PEG-IFN) plus ribavirin were reanalyzed with the CAP/CTM v2.0. Samples from 16 patients had previously been tested with the CAP/CA and HPS/CA and samples from five patients with the CAP/CTM v1.0. Retesting resulted in three changes in response interpretations relative to the previous performed test. One week 4 sample from a patient with a high baseline viral load (6.9 log IU/ml) and a complete early virological response (cEVR), previously tested and found to be HCV RNA positive with the CAP/CA (interpretation, no rapid virological response [RVR]), tested negative in the CAP/CTM v2.0 (interpretation, RVR). Both results would have resulted in a recommendation of 48 weeks of treatment according to the treatment guideline (15) . Another week 4 sample from another patient with a high baseline viral load (6.2 log IU/ml) that was previously tested and found to be negative with the CAP/CA retested positive (1.17 ϫ 10 3 IU/ml) in the CAP/ CTM v2.0. In this case also, both results would have indicated 48 weeks of treatment. The result of a third sample that was discrepant after retesting would have had a significant effect on therapy duration. The week 24 sample of a patient with no RVR and an EVR was previously tested and found to be negative with the CAP/ CTM v1.0 and therefore was advised 72 weeks therapy, under which the patient experienced a relapse. The week 24 sample tested positive after retesting with the CAP/CTM v2.0 and would therefore have resulted in a recommendation to stop treatment after 24 weeks according to treatment guidelines.
DISCUSSION
In the present article, we show that the CAP/CTM v2.0 has significantly improved analytical and clinical performance characteristics compared to the previous version. Furthermore, the sensitivity of the CAP/CTM v2.0 was close to that of the TMA on genotypes 1 to 4. Good precision and high sensitivity for HCV genotypes 1 to 6 indicate that CAP/CTM v2.0 is a good test for monitoring the HCV load during treatment.
Recently, an improved prototype version of the CAP/CTM HCV real-time quantitative RT-PCR was described (11) . CAP/ CTM v1.0 has been shown to underquantify certain genotype 4 samples while overestimating the viral load of other genotypes (8) . In addition, two polymorphisms in the region where the probe anneals could also result in false-negative results (11) . In the present article, we set out to analyze the quantitative analytical performance of the CAP/CTM v2.0 test relative to the Realtime test and the bDNA assay. In addition, the qualitative performance relative to the TMA test and the clinical performance in a small cohort of genotype 4-infected individuals treated with PEG-IFN plus ribavirin were analyzed.
No significant differences in quantification were observed relative to the Realtime test for any of the six genotypes. The genotype quantification of the bDNA assay relative to the Realtime and the CAP/CTM v2.0 was variable; the bDNA test seemed to underquantify genotypes 2, 3, and 6, while similar results relative to its comparators were obtained for genotypes 1, 4, and 5. Similar to previously published data, the CAP/CTM v1.0 overestimated HCV loads in samples with genotypes 1, 3, 5, and 6 while underestimating viral loads in genotype 2 and 4 samples (8) . Also, in our analysis, 4 samples (1 genotype 1 and 3 genotype 4) that carried the mutation G145A in combination with A165T in the 5=UTR were identified, which seriously compromised the quantitation by the CAP/CTM v1.0. The CAP/CTM v2.0 correctly quantified these samples relative to the Realtime and bDNA tests.
Currently, the most sensitive test for the detection of HCV RNA is the qualitative TMA, with a LLOD of approximately 5 IU/ml, although a head-to-head comparison with the Realtime assay and CAP/CTM v1.0 and v2.0 has not yet been published (3, 16) . In our analysis, only 3 of the 34 bDNA-negative, TMA-positive samples from patients on treatment who were infected with genotype 1, 2, 3, or 4 were not detected by the CAP/CTM v2.0 in the qualitative data set. In our qualitative data set, the CAP/CTM v2.0 had a slightly lower sensitivity for genotype 4 relative to the TMA whereas the performance for genotypes 1 and 3 was similar to that of the TMA test. Given the fact that the results of quantitative and qualitative detection of genotype 4 HCV RNA are comparable to the Realtime assay results, it seems unlikely that the slightly lower sensitivity below the LLOQ of the CAP/CTM v2.0 (15 IU/ml) relative to the TMA for genotype 4 would have a significant impact on clinical performance characteristics. Current guidelines for the treatment of HCV recommend response-guided therapy monitored with a sensitive real-time RT-PCR-based assay. Given the sensitivity of the qualitative results and the good genotype inclusivity of the quantitative results, it may be assumed that the CAP/CTM v2.0 can be used worldwide for responseguided treatment of HCV. The robustness of the assay in diverse laboratory settings and for genotypes encountered worldwide still needs to be elucidated, however. In a small cohort of genotype 4 HCV-infected patients on treatment with PEG-IFN plus ribavirin, 16 of whom had previously been monitored with the CAP/CA and 5 with the CAP/CTM v1.0, the CAP/CTM v2.0 performed comparably to the CAP/CA but better than the CAP/CTM v1.0. In one patient, monitoring with the CAP/CTM v2.0 instead of the CAP/ CTM v1.0 would have led to an earlier prediction of therapy failure and thus to shortening of therapy.
